Taking oestradiol therapy within 6 years after the start of menopause significantly delayed lipid plaque buildup in arterial walls — a leading cause of atherosclerosis, but such benefit was not seen when starting oestradiol a decade after menopause, reveals a secondary analysis of the ELITE* study presented at the recent EPI Lifestyle 2020 Scientific Sessions.
Women with primary Sjögren’s syndrome experience vaginal dryness, which contributes to sexual dysfunction and dyspareunia, as reported in a study. The dryness may be attributed to a peri-epithelial infiltration and decreased number of vascular smooth muscle cells in the vaginal wall.
Treatment with the dual neurokinin 1,3 antagonist NT-814 induces prompt, marked improvements in hot flashes and waking due to night sweats in postmenopausal women, with doses up to 300 mg being well tolerated, according to the results of a trial.
Increased consumption of fruits and vegetables appears to alleviate menopausal symptoms, although higher intake of certain types such as leafy greens and citrus fruits contributes to increased urogenital symptoms, a study has found.
Treatment with the ultra-low dose 0.005% estriol vaginal gel yields improvements in symptoms and signs of vulvovaginal atrophy, with minimal oscillations in hormonal levels, according to the results of a phase II trial.
Dr. Hang Wun Raymond Li, Prof. Pak-Chung Ho, Dr. Ernest Hung Yu Ng, 20200317000000
Anti-Müllerian hormone (AMH) was initially recognized as the factor that
determines regression of the Müllerian duct in the male foetus and
hence plays an important role in male sex differentiation. Production of
AMH in adult women was first reported in 1990.1 In the past two
decades, its role in female ovarian function and the clinical utilities
of serum AMH level has been increasingly studied.
Postmenopausal women are likely to have slightly higher depressive symptoms relative to their premenopausal counterparts, although the association between menopause and mental well-being varies with the level of physical activity (PA), a study has shown.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.